# All the Way: A Decade of SIRT1 in Breast Cancer

## TL;DR

This paper reviews SIRT1's complex role in breast cancer, especially triple-negative breast cancer, and its potential as a therapeutic target.

## Contribution

The paper provides a comprehensive review of SIRT1's dual roles and regulatory mechanisms in breast cancer over the past decade.

## Key findings

- SIRT1 can act as both a tumor suppressor and an oncogene in breast cancer.
- SIRT1 activity is regulated by miRNAs and can be modulated through natural extracts.
- The role of SIRT1 in triple-negative breast cancer remains controversial and requires further study.

## Abstract

Breast cancer (BC) is a highly heterogeneous genetic disease, comprising several subtypes with distinct features that significantly influence prognosis and treatment outcomes. Among these subtypes, triple-negative breast cancer (TNBC) is particularly aggressive and makes it resistant to many standard therapies. Epigenetic mechanisms, including acetylation and deacetylation, are crucial in regulating gene expression and maintaining normal cellular functions and are closely associated with BC progression. In this context, the histone deacetylases sirtuins (SIRT1-7) regulate key biological processes like genomic stability, inflammation, cellular senescence, and metabolic functions, increasingly linked to cancer. In particular, SIRT1 shows dual roles, functioning both as a tumor suppressor or an oncogene, contributing to cancer initiation, progression, and metastasis as well as chemotherapy resistance. Despite extensive research in the past decade, the exact role of SIRT1 in BC, especially in TNBC, remains controversial. Recent findings suggest that SIRT1 can be modulated not only through pharmacological approaches but also using natural extracts, offering potential alternative or complementary therapeutic strategies. Additionally, SIRT1 activity is regulated by a complex network of miRNAs, highlighting the need for further investigation. This review aims to summarize recent studies to identify key insights into the role of SIRT1 and explore it as a potential therapeutic target in BC.